Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

• Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
• Presentation of a new tyrosine kinase inhibitor
• Generics making it into practice
• Predictive markers and their impact on patients outcome
• Considerations for treatment discontinuation in clinical practice including AE management

{rscomments off}